Background First-line chemotherapy for advanced or metastatic human epidermal growth
factor receptor 2 (HER2)-negative gastric or gastro-oesophageal junction adenocarcinoma …

Immune checkpoint inhibitor (ICI) treatments benefit some patients with metastatic cancers,
but predictive biomarkers are needed. Findings in selected cancer types suggest that tumor …

Tumor molecular profiling is a fundamental component of precision oncology, enabling the
identification of genomic alterations in genes and pathways that can be targeted …

Purpose With prospective clinical sequencing of tumors emerging as a mainstay in cancer
care, an urgent need exists for a clinical support tool that distills the clinical implications …

Human epidermal growth factor receptor 2 (HER2, also known as ERBB2) amplification or
overexpression occurs in approximately 20% of advanced gastric or gastro-oesophageal …

EGF receptor (EGFR)–mutant lung cancers eventually become resistant to treatment with
EGFR tyrosine kinase inhibitors (TKI). The combination of EGFR-TKI afatinib and anti-EGFR …

Metastatic progression is the main cause of death in cancer patients, whereas the underlying
genomic mechanisms driving metastasis remain largely unknown. Here, we assembled …

Standard first-line chemotherapy results in disease progression and death within one year
in most patients with human epidermal growth factor receptor 2 (HER2)-negative gastro-…

Purpose Metastatic esophagogastric cancer treatments after failure of second-line chemotherapy
are limited. Nivolumab demonstrated superior overall survival (OS) versus placebo in …

PURPOSE Microsatellite instability (MSI) and/or mismatch repair deficiency (MMR-D) testing
has traditionally been performed in patients with colorectal (CRC) and endometrial cancer (…